CTLA4 and breast cancer: BC was considered a non-immunogenic tumor entity before analyzing TIL infiltration [83] At current, the application of T cell-mediated immunotherapy of CTLA-4 [84, 85] and PD-L1 inhibitors [86] in combination with standard of care BC therapy in BC patients is quite promising [87].